Activities of Teresa JIMÉNEZ-BECERRIL BARRIO related to 2016/2057(INI)
Shadow opinions (1)
OPINION on EU options for improving access to medicines
Amendments (12)
Amendment 4 #
Draft opinion
Paragraph 1
Paragraph 1
1. Recalls that Sustainable Development Goal 3, with nine quantitative and four qualitative targets, clearly states that by 2030 everyone should have access to good mental and physical health throughout their lives; underlines that, each year, 100 million people fall into poverty because of health costs which are disproportionate to their incomes, and that, according to the WHO, over one third of the world’s population, with over 50 % in Africa, does not have access to safe, effective and affordable medicines;
Amendment 8 #
Draft opinion
Paragraph 1 a (new)
Paragraph 1 a (new)
1a. Recognises that developing medicines and medical research is a multibillion business which indicates the complexity of providing easy access to medicines for developing countries which requires the need for proper national and international legislation to remove the obstacles for developing countries to have access to medicine;
Amendment 27 #
Draft opinion
Paragraph 2
Paragraph 2
Amendment 35 #
Draft opinion
Paragraph 2 a (new)
Paragraph 2 a (new)
2a. Calls on the EU to actively promote innovative practices in the pharmaceutical sector that give priority to access-oriented pricing strategies in developing countries, and put a greater focus on neglected and non- communicable diseases;
Amendment 43 #
Draft opinion
Paragraph 3
Paragraph 3
3. Supports competition in generic medicines, which allows broad access to medicines in LMICs; calls, in particular, for the EU to support actively governments that use the available legal measures, including TRIPS safeguards and flexibilities, to protect and promote public health; calls also for the EU to immediately stop targeting countries such asoften its approach towards India that have implemented progressive TRIPS- compliant IP policies which promote access to medicines, through its watch-list of ‘'priority countries’';
Amendment 47 #
Draft opinion
Paragraph 3 a (new)
Paragraph 3 a (new)
3a. Recognises the importance of developing generic medicines for developing countries while at the same time supporting investment for research and development of new drugs;
Amendment 48 #
Draft opinion
Paragraph 3 b (new)
Paragraph 3 b (new)
3b. Believes that achieving access to medicines for all is a shared responsibility between public and private actors; stresses the importance of encouraging multi- stakeholder partnerships and ensuring the full participation of private sector and civil society in the definition of health;
Amendment 59 #
Draft opinion
Paragraph 4
Paragraph 4
4. Stresses that, without transparency of research and development costs to originator companies and information on the actual prices paid for medicines across the EU, any discussion on fair medicine prices remains impossible; recalls the Commission’s commitment to greater transparency of EU positions, specific legal proposals, and negotiating texts in the TTIP negotiations;
Amendment 67 #
Draft opinion
Paragraph 5
Paragraph 5
5. Urges to take advantage ofWelcomes the ongoing review process of the EU Tiered Pricing Regulation to repeal it unless it can be amended, in close collaboration with the Commission’s Directorates- General for International Cooperation and Development (DG DEVCO) and for Health and Food Safety (DG SANTÉ), in order to support all measures that countries have at their disposal to ensurebetter ensure a worldwide access to affordable access to medicines.;
Amendment 72 #
Draft opinion
Paragraph 5 a (new)
Paragraph 5 a (new)
5a. Highlights that women and children have less access to medicines in developing countries than adult men due to a lack of availability, accessibility, affordability and acceptability in terms of discrimination based on cultural, religious or social factors, and poor quality of health facilities;
Amendment 74 #
Draft opinion
Paragraph 5 b (new)
Paragraph 5 b (new)
5b. Warms that the global incidence of dengue fever has grown dramatically in recent decades, particularly in tropical and sub-tropical developing countries, and that the lack of proper medication to reduce the symptoms of dengue fever will worsen the situation as early detection and access to proper medical care reduces fatality rates below 1%;
Amendment 75 #
Draft opinion
Paragraph 5 c (new)
Paragraph 5 c (new)
5c. Urges the need for an international rapid emergency unit, coordinated between public and private sector, to immediately provide proper medicines for patients in the developing world who are suffering from a viral or bacterial outbreak;